Review of gout clinic in a tertiary hospital setting.
Aged
Aged, 80 and over
Ambulatory Care
/ statistics & numerical data
Australia
Disease Management
Female
Gout
/ blood
Gout Suppressants
/ therapeutic use
Guideline Adherence
Hospitalization
Humans
Linear Models
Male
Middle Aged
Practice Guidelines as Topic
Retrospective Studies
Tertiary Care Centers
Treatment Outcome
Uric Acid
/ blood
gout clinic
gout management
gout treatment
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
22
04
2019
revised:
27
07
2019
accepted:
05
08
2019
entrez:
17
1
2020
pubmed:
17
1
2020
medline:
5
11
2020
Statut:
ppublish
Résumé
Although updated consensus guidelines, and effective therapies, are available for management of gout, suboptimal management remains an issue. Barriers were identified and addressed as part of a dedicated, structured gout clinic. More frequent appointments resulted in a faster rate of serum urate reduction, and the clinic provided the opportunity for the education of both patients and general practitioners in the management of gout.
Substances chimiques
Gout Suppressants
0
Uric Acid
268B43MJ25
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-120Informations de copyright
© 2020 Royal Australasian College of Physicians.
Références
Ting K, Gill TK, Keen H, Tucker GR, Hill CL. Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study. Intern Med J 2016; 46: 566-73.
Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R et al. The global burden of gout: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014; 73: 1470-6.
Rai SK, Choi HK, Choi SHJ, Townsend AF, Shojania K, De Vera MA. Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies. Rheumatology (Oxford) 2018; 57: 1282-92.
Eliseev M, Zhelyabina O, Chikina M, Vladimirov S. Assessment of therapy adherence and treatment results in gout patients who attended schools for patients and in those who did not. Ann Rheum Dis 2018; 77: 654.
Slot O. Gout in a rheumatology clinic: results of EULAR/ACR guidelines-compliant treatment. Scand J Rheumatol 2018; 47: 194-7.
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64: 1431-46.
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76: 29-42.
Sivera F, Andres M, Carmona L, Kydd AS, Moi J, Seth R et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014; 73: 328-35.
Perez-Ruiz F, Moreno-Lledo A, Urionaguena I, Dickson AJ. Treat to target in gout. Rheumatology (Oxford) 2018; 57: i20-6.
Pascart T, Liote F. Gout: state of the art after a decade of developments. Rheumatology (Oxford) 2019; 58: 27-44.
Ar'ev AL, Kunitskaia NA, Kozina LS. Gout and hyperuricemia today: prevalence, risk factors, features in the elderly. Adv Gerontol 2012; 25: 540-4.
Robinson PC, Taylor WJ, Dalbeth N. An observational study of gout prevalence and quality of care in a national Australian general practice population. J Rheumatol 2015; 42: 1702-7.
Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 2015; 11: 649-62.
Stamp LK, Chapman PT. Urate-lowering therapy: current options and future prospects for elderly patients with gout. Drugs Aging 2014; 31: 777-86.
Aung T, Myung G, FitzGerald JD. Treatment approaches and adherence to urate-lowering therapy for patients with gout. Patient Prefer Adherence 2017; 11: 795-800.
Perez-Ruiz F, Richette P, Karra RG, Wild I, Hagedorn H, Kandaswamy P et al. Effect of serum uric acid (SUA) on gout flares (GF) and tophi resolution in gout patients. pooled post hoc analysis of clear 1 & clear 2 trials. Ann Rheum Dis 2018; 77: 658-9.
Sarapulova A, Teplyakova O, Popov A, Popova T, Palabugina P. Patients compliance to chronic gout therapy when administered by different medical professionals. Ann Rheum Dis 2018; 77: 1627.
Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 2018; 392: 1403-12.
Lin LW, Teng GG, Lim AYN, Yoong JS, Zethraeus N, Wee HL. Cost-effectiveness of an adherence-enhancing intervention for gout based on real-world data. Int J Rheum Dis 2019; 22: 545-54.